Agios Pharmaceuticals (AGIO) : During the past 4 weeks, traders have been relatively bearish on Agios Pharmaceuticals (AGIO), hence the stock is down -4.15% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.31% relative to the S&P 500. The 4-week change in the price of the stock is -3.16% and the stock has fallen -6.26% in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.67% and the 50-Day Moving Average is 12.28%. Agios Pharmaceuticals (NASDAQ:AGIO): stock turned positive on Friday. Though the stock opened at $40, the bulls momentum made the stock top out at $40.498 level for the day. The stock recorded a low of $39.87 and closed the trading day at $40.42, in the green by 1.23%. The total traded volume for the day was 584,858. The stock had closed at $39.93 in the previous days trading.
The company Insiders own 10.55% of Agios Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -12.72% . Institutional Investors own 88.2% of Agios Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -14.4%. Also, Brokerage firm Canaccord Genuity upgrades its rating on Agios Pharmaceuticals (NASDAQ:AGIO). As per the latest information, the brokerage house raises the price target to $90 per share from a prior target of $50. The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by the firm was issued on June 13, 2016.
Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.